Incidence and Risk of Influenza in Myasthenic Patients

Upper Respiratory Infection Clinical Trial

Official title:

Incidence and Risk of Influenza in Myasthenic Patients Hospitalized in Intensive Care

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03884777
• Other study ID #: CIC1429
• Status: Completed
• Start date: January 1, 2009
• Est. completion date: December 31, 2017

Study information

• Verified date: December 2017
• Source: Centre d'Investigation Clinique et Technologique 805
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Upper respiratory infection , including influenza, may exacerbate the symptoms of myasthenia gravis (MG), which is an autoimmune disease that causes muscle weakness and, in some cases, can precipitate a myasthenic crisis

In the present study, we investigated the incidence and risk factors of influenza infection on in myasthenia gravis patients.

Description:

This is a descriptive study. The data will be analyzed retrospectively . Inclusion of 416 cases of influenza in myasthenic patients treated in the intensive care unit of Garches Hospital between January 1, 2009 and December 31, 2017.

Patients who meet the inclusion and non inclusion criteria and do not object to participate in the study will be collected in a database for analysis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 400
• Est. completion date: December 31, 2017
• Est. primary completion date: December 31, 2017
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men or women over the age of 18.

• Myasthenic patients hospitalized in intensive care.

• Patients with confirmed influenza infection

Exclusion Criteria:

• Age <18 years,

• Other neuromuscular diseases,

• Patient opposing the use of his data

Related Conditions & MeSH terms

• Influenza, Human
• Myasthenic Crisis
• Respiratory Tract Infections
• Upper Respiratory Infection

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Centre d'Investigation Clinique et Technologique 805

References & Publications (4)

Friman G, Schiller HH, Schwartz M. Distubed neuromuscular transmission in viral infections. Scand J Infect Dis. 1977;9(2):99-103. — View Citation

Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol. 2018 Jan;16(1):60. doi: 10.1038/nrmicro.2017.146. Epub 2017 Nov 7. — View Citation

Rosciszewska D, Bluszcz M, Kurek H. [Antibodies for DNA and RNA viruses in the serum of myasthenia patients. Preliminary report]. Neurol Neurochir Pol. 1981 Sep-Dec;15(5-6):541-4. Polish. — View Citation

Tackenberg B, Schneider M, Blaes F, Eienbröker C, Schade-Brittinger C, Wellek A, Deschauer M, Eickmann M, Klenk HD, Müller HH, Sommer N. Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gra — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of influenza in myasthenic patient in crisis	Number of influenza cases in myasthenic patients	between January 1, 2009 and December 31, 2017.
Secondary	Risk factors for poor outcomes	To identify risk factors for severe influenza in myasthenic patients	between January 1, 2009 and December 31, 2017.